Today, the World Health Organization (WHO) clarified that it cannot cut corners to recommend Covaxin’s inclusion in the Emergency Use Listing (EUL) for vaccination against COVID-19. The organization mentioned that it is expecting one additional piece of information from the Covaxin manufacturer.
Talking to the media, the UN health agency informed that several are still waiting for WHO’s recommendation for Covaxin to be included in the ‘COVID19 Emergency Use Listing’. “We cannot cut corners – before recommending a product for emergency use. We must evaluate it thoroughly to make sure it is safe and effective,” WHO added.
The approval by WHO is mandatory for Covaxin’s emergency use authorization, for its widespread acceptability as a safe and effective vaccine around the world. The emergency listing of the Bharat Biotech vaccine will encourage other countries to ease travel measures for those vaccinated with the India-made vaccine.
Commenting on the timeframe for the WHO Emergency Use Listing procedure, the organization stated that it is dependent on how quickly a company producing the vaccine can provide the data required. These data are needed by WHO to evaluate and study the vaccine’s quality, safety, efficacy, and suitability for low- and middle-income countries.
The chief scientist of WHO, Soumya Swaminathan informed that the technical advisory group will meet on October 26 to decide on the emergency use listing of Covaxin. She mentioned that WHO’s goal is to have a broad portfolio of vaccines approved for emergency use and to expand access to populations everywhere.